Camellia flower composition with soothing and repairing effects as well as preparation method and application thereof

Abstract

The invention discloses a camellia flower composition with soothing and repairing effects as well as a preparation method and application of the camellia flower composition. The camellia oil composition is prepared from the following raw materials in percentage by weight: 5 to 99.0 percent of camellia extract, 0.01 to 5.0 percent of 4-tert-butyl cyclohexanol, 0.01 to 2.0 percent of bisabolol, 0.001 to 5.0 percent of stearyl glycyrrhetinate, 0.001 to 2.0 percent of artemisia apiacea extract and 0.001 to 2.0 percent of chamomile essential oil, and a solvent is used for supplementing the raw materials. The invention further discloses a preparation method of the camellia composition and application of the camellia composition in preparation of skin care products with soothing and repairing effects. The camellia flower composition can down-regulate the relative expression quantity of TNF-alpha and IL-17RA genes, has the effect of improving the cell migration rate, blocks anaphylactic reaction through directional multi-target and multi-path, resists damage of ultraviolet light to skin, repairs damaged barriers, reshapes skin health, and safely and effectively achieves the effects of relieving and repairing.

Description

Technical Field

[0001] This invention relates to the field of cosmetic technology, specifically to a camellia composition with soothing and repairing effects, its preparation method and application, which has the effects of blocking allergic reactions at multiple targets and through multiple pathways, repairing damaged barriers, and restoring skin health. Background Technology

[0002] Sensitive skin is prone to dryness, tightness, itching, stinging, sensitivity, redness, and persistent, recurring symptoms after exposure to external stimuli, which can accelerate skin aging. In recent years, the incidence of sensitive skin has been gradually increasing, seriously affecting people's quality of life and becoming a global health issue that has received widespread attention.

[0003] The demand for skincare products for sensitive skin is constantly rising. The causes of skin sensitivity are diverse, and the resulting symptoms vary. Currently, there are more and more soothing cosmetics on the market, but their quality varies greatly. Most rely on a single approach—gentleness, simple ingredients, and repairing the skin barrier—to improve the skin's existing irritation. However, the effect of a single soothing mechanism is limited. Summary of the Invention

[0004] To address the aforementioned technical problems, the present invention aims to provide a camellia composition with soothing and repairing effects, its preparation method, and its application. The composition of the present invention utilizes a soothing mechanism and the mechanism of sensitive skin development to target multiple points and pathways to block allergic reactions, repair damaged skin, and achieve significant soothing and repairing effects.

[0005] The objective of this invention is achieved through the following technical solution:

[0006] In a first aspect, the present invention provides a camellia composition with soothing and repairing effects, the composition comprising the following components in weight percentages: Camellia extract 5-99.0%, 4-tert-butylcyclohexanol 0.01~5.0%, Bisabolol 0.01~2.0%, Stearyl glycyrrhetinic acid ester 0.001~5.0%, Artemisia annua extract 0.001~2.0%, Chamomile essential oil 0.001~2.0%, Replenish the solvent to 100%.

[0007] In one embodiment of the present invention, the camellia extract includes camellia seed oil, camellia flower extract and camellia leaf extract, with a mass ratio of 70-99.8:0.1-15:0.1-15.

[0008] As some specific embodiments of the present invention, the purity of the 4-tert-butylcyclohexanol is ≥99% (tested by HPLC and HNMR). And / or, the bisabolol is of natural origin, wherein the purity of levo-α-bisabolol is ≥95%; And / or, the purity of the stearyl glycyrrhetinic acid ester is ≥98%.

[0009] In one embodiment of the present invention, both 4-tert-butylcyclohexanol and stearyl glycyrrhetinic acid ester are solid powders. The solubility of stearyl glycyrrhetinic acid ester in oils and fats is limited. 4-tert-butylcyclohexanol can inhibit TRPV1 expression and alleviate neurosensitivity reactions. It is hydrophilic and can interact with polar molecules through hydrogen bonds, helping to dissolve or disperse polar substances. Simultaneously, the relatively large hydrophobic tert-butyl group (-C(CH3)3) can bind with non-polar components (such as terpenes in oils and fragrances) through van der Waals forces, enhancing its solubility for fat-soluble substances. The strong electron-donating effect of the tert-butyl group and the stability of the cyclohexanol skeleton make it less prone to reacting with other components, ensuring the stability of the dissolution process. 4-tert-butylcyclohexanol can inhibit TRPV1 expression and alleviate neurosensitivity reactions, while simultaneously achieving efficient dissolution and stabilization of multiple components in cosmetics.

[0010] As some specific embodiments of the present invention, the artemisia extract includes one or more of Artemisia annua extract and Artemisia annua leaf extract.

[0011] As some specific embodiments of the present invention, the chamomile essential oil includes one or more of Roman chamomile essential oil (white chamomile flower oil) and German chamomile essential oil.

[0012] As some specific embodiments of the present invention, the solvent includes natural oils or synthetic oils, specifically, the solvent is selected from caprylic / capric triglycerides or squalane.

[0013] The composition of this invention contains camellia seed oil, which can repair damaged skin barriers; camellia flower extract, which can resist UV damage to the skin; camellia leaf extract, which can fight free radicals and enhance antioxidant defense; 4-tert-butylcyclohexanol, which can inhibit TRPV1 expression and alleviate neurosensitivity reactions; stearyl glycyrrhetinic acid ester, which can enhance the stability of mast cell membranes and soothe skin immune inflammatory responses; bisabolol, which can significantly reduce the expression of inflammatory factors, reduce inflammation levels, prevent the release of sensitizing mediators, and reduce vascular reactions; artemisia annua extract, which can significantly reduce the level of inflammatory cells and block histamine release; and Roman chamomile essential oil, which has antibacterial and anti-inflammatory properties, inhibits wound infection, and promotes wound healing. The composition has eight targets working together, complementing each other and synergistically enhancing the effect. Simultaneously, by inhibiting TRAF6 activation and blocking IL-17 signal transduction, it blocks the generation of sensitizing factors from the source, achieving anti-inflammatory and soothing effects. It effectively improves symptoms such as skin redness, itching, tightness, peeling, stinging, burning, childhood eczema, and skin allergies. The composition of this invention can be used as an active ingredient in skincare essential oil products.

[0014] Secondly, the present invention provides a method for preparing a camellia composition with soothing and repairing effects as described in any of the preceding claims, comprising the following steps: S1, A phase preparation: Camellia extract, 4-tert-butylcyclohexanol and stearyl glycyrrhetinic acid ester were weighed into solvent according to mass percentage, mixed, heated and stirred until completely clear and transparent to obtain phase A mixture; S2, B phase preparation: Weigh bisabolol, artemisia annua extract and chamomile essential oil according to the mass percentage, mix and stir evenly until completely clear and transparent to obtain the B phase mixture; S3, A, B phase mixture: While stirring, slowly add the B phase mixture to the A phase mixture, and stir until it is uniform and transparent.

[0015] As some specific embodiments of the present invention, in step S1, the temperature of heating and stirring is 80-90 ℃.

[0016] Thirdly, the present invention provides the application of a camellia composition with soothing and repairing effects as described in any of the preceding claims in the preparation of skin care products.

[0017] As some specific embodiments of the present invention, the skin care products include essential oils, creams, lotions, or masks.

[0018] Weigh the composition directly and add it to the skin care product formula at 50°C. Stir well and homogenize if necessary.

[0019] Compared with the prior art, the present invention has the following beneficial effects: (1) Based on the research findings on the mechanism of sensitive skin, this invention designs and combines soothing and repairing active ingredients from the perspectives of influencing factors and cell efficacy verification. These active ingredients work through eight precise target pathways at three levels: preventing external contact irritation, preventing endogenous allergens and blocking sensitizing reaction factors, and restoring skin health to achieve long-term stability and repair sensitive skin from the root. Thus, it is scientifically and rationally designed to play a comprehensive role as much as possible and safely and effectively achieve the effects of soothing and repairing.

[0020] (2) In the composition of the present invention, camellia seed oil can repair the skin barrier; camellia flower extract can resist ultraviolet light damage to the skin; camellia tea leaf extract can resist free radicals and enhance antioxidant defense; 4-tert-butylcyclohexanol can inhibit the expression of TRPV1 and alleviate neurosensitivity; stearyl glycyrrhetinic acid ester inhibits the NF-κB and TNF-α signaling pathways, reduces the secretion of endothelin-1 (ET-1), IL-1α, and PGE2, enhances the stability of mast cell membranes, and soothes the skin's immune inflammatory response; bisabolol can significantly reduce the expression of NF-κB and IL-1β inflammatory factors. It reduces inflammation levels, prevents the release of sensitizing mediators, and lowers vascular reactivity; Artemisia annua extract can significantly reduce NO and IL-6 levels in inflammatory cells and block histamine release; Roman chamomile essential oil significantly inhibits the activity of hyaluronic acid, enzymes, and tyrosinase, while also inhibiting Staphylococcus aureus, Staphylococcus epidermidis, and Pseudomonas aeruginosa, and promoting the migration of HSF or HaCaT cells, which is beneficial for inhibiting wound infection and promoting wound healing; the eight targets work together, complement each other, and synergistically enhance the soothing effect, effectively improving symptoms such as skin redness, itching, tightness, peeling, stinging, burning, childhood eczema, and skin allergies.

[0021] (3) The camellia composition of the present invention can also block IL-17 signal transduction by inhibiting the activation of TRAF6, thereby blocking the generation of sensitizing factors from the source and achieving anti-inflammatory and soothing effects. The mechanism of action of blocking IL-17 signal transduction is as follows: IL-17A / F activates the Act1-TRAF6 signal axis by binding to the IL-17RA / RC receptor, induces the NF-κB and MAPK pathways, promotes the release of pro-inflammatory factors such as IL-6 and TNF-α from keratinocytes, and forms an inflammatory cascade amplification effect.

[0022] (4) The composition of the present invention has lipophilic properties, which can easily penetrate the stratum corneum of the skin to achieve multi-functional and multi-target delivery of active ingredients into various layers of the skin, improve the stability of active ingredients, and enable active ingredients to achieve sustained-release and long-lasting effects.

[0023] (5) Camellia flowers, tea leaves, stearyl glycyrrhetinic acid esters have limited solubility in oils. When added to transparent essential oil formulations, they are prone to instability and precipitation. To solve the problem of formulation application, this invention designs and uses a safe solvent combination suitable for cosmetics, combining the active ingredients into a stable system, based on the chemical structure of the active ingredients. The stability test results show that this composition is uniform and stable, with no precipitation. Moreover, the formulation application is simple and can be directly added to the formulation system at low temperature. Attached Figure Description

[0024] Other features, objects, and advantages of the present invention will become more apparent from the following detailed description of non-limiting embodiments with reference to the accompanying drawings: Figure 1 The graph shows a comparison of the relative expression levels of IL-17RA and TNF-α genes at different concentrations of the composition in Example 1. Figure 2 This is a comparison chart of cell migration rate test results for different experimental groups in Example 2. Detailed Implementation

[0025] The present invention will now be described in detail with reference to specific embodiments. These embodiments will help those skilled in the art to further understand the present invention, but do not limit the invention in any way. It should be noted that those skilled in the art can make various modifications and improvements without departing from the concept of the present invention. These all fall within the scope of protection of the present invention.

[0026] Examples 1-3 The formulations for Examples 1-3 are shown in Table 1, and each was prepared according to the following steps: 1. Preparation of Phase A: Weigh the solvent (caprylic / capric triglyceride), camellia extract, 4-tert-butylcyclohexanol, and stearyl glycyrrhetinic acid ester according to the mass percentage, mix and heat to 80-90℃, stir and dissolve until completely clear and transparent, to obtain the Phase A mixture, which is a transparent light yellow liquid. 2. Preparation of Phase B: Weigh bisabolol, Artemisia annua leaf extract and Chrysanthemum morifolium oil by mass percentage and stir until completely clear and transparent to obtain the Phase B mixture, which is a transparent light yellow liquid; 3. Mixing phases A and B: While stirring, slowly add phase B mixture to phase A mixture and stir until a transparent light yellow mixture is obtained.

[0027] Table 1 Formulation Table of Examples

[0028] In Table 1, the extraction method of camellia seed oil is carried out in accordance with Example 1 of patent CN111218335B; the extraction methods of camellia flower extract and camellia leaf extract are as follows: after crushing and sieving red camellia flowers and red camellia leaves respectively, supercritical CO2 extraction is carried out, wherein the extraction pressure is 20 MPa, the extraction temperature is 35°C, and the extraction time is 2 h.

[0029] Artemisia annua leaf extract (Artemisia annua extract) was purchased from Hunan Siyikang Biotechnology Co., Ltd., and Chamomile spp. flower oil (Roman chamomile essential oil) was purchased from Yaqi Industrial (Shanghai) Co., Ltd.

[0030] Comparative Examples 1-4 The formulations of Comparative Examples 1-4 are shown in Table 2, and were prepared according to the methods of the Examples.

[0031] Table 2 Comparative Formula Table

[0032] Example 1 – Relative Expression Levels of TNF-α and IL-17RA Genes 1. Take the compositions prepared in each example and comparative example, dilute with dimethyl sulfoxide to 0.05% (w / w), and test the relative expression levels of TNF-α and IL-17RA genes. The soothing efficacy of the samples is evaluated by detecting the relative expression levels of IL-17RA and TNF-α genes in keratinocytes after sample treatment.

[0033] The results are shown in Table 3 below: Table 3. Results of gene relative expression level test

[0034] From the above results, we can conclude that: Comparative Example 1 used only the solvent as the base material, without adding camellia extract or other soothing ingredients. The results showed that the downregulation rates of TNF-α and IL-17RA were both 0, serving as the baseline control.

[0035] The only difference between Comparative Example 2 and Comparative Example 1 is that only camellia extract was added to the base material of Comparative Example 1, without adding its soothing components. The results showed that the relative downregulation rate of TNF-α and IL-17RA genes was significantly higher than that of Comparative Example 1.

[0036] The only difference between Comparative Example 3 and Comparative Example 1 is that, in addition to Camellia Extract, other soothing ingredients were added to the base ingredient Comparative Example 1. The results showed that the relative expression rates of TNF-α and IL-17RA genes were significantly improved compared to Comparative Example 1, but not as good as those of Comparative Example 2.

[0037] Example 1, based on the base material Comparative Example 1, added camellia extract and other soothing ingredients, but still used solvent as the main component. The results showed that Example 1 significantly improved the downregulation rate of the relative expression levels of TNF-α and IL-17RA genes compared with Comparative Example 2 and Comparative Example 3.

[0038] Example 2, based on Example 1, further increased the amount of camellia extract. The results showed that, compared with Example 1, the downregulation rate of the relative expression levels of TNF-α and IL-17RA genes was significantly improved.

[0039] Example 3, based on Example 2, further removed the solvent and increased the proportion of camellia extract and other soothing ingredients. The results showed that the downregulation rate of the relative expression levels of TNF-α and IL-17RA genes was significantly improved compared with Example 2.

[0040] The only difference between Comparative Example 4 and Example 3 is that no other soothing ingredients were added to Example 3, and only camellia extract was included. The results showed that the relative expression rates of TNF-α and IL-17RA genes were significantly improved compared to Comparative Example 2, but not as good as those of Example 3.

[0041] The above results indicate that camellia extract and other soothing ingredients have a synergistic effect on the downregulation of the relative expression levels of TNF-α and IL-17RA genes.

[0042] TNF-α is a pro-inflammatory cytokine secreted by immune cells (such as macrophages) and participates in the initiation and amplification of inflammatory responses. IL-17RA is an interleukin-17 receptor type A, belonging to the cytokine receptor family, not the cytokine itself. It primarily acts as a co-receptor for the IL-17 family (such as IL-17A / F), mediating signal transduction and participating in mucosal immunity and inflammatory responses, promoting inflammation by activating the NF-κB pathway. This invention has found that camellia extract and camellia flower compositions containing other soothing ingredients can downregulate the relative expression of IL-17RA and, by promoting the downregulation of TNF-α and IL-17RA gene expression, reduce the expression of inflammatory factors, thus having a soothing effect on the skin.

[0043] 2. The composition of Example 3 was diluted to different concentrations (0.0125%, 0.025%, 0.05%), and a model control group (0.0125%, 0.025%, 0.05% of the camellia extract in the formulation of Example 3) and a blank control group were set up. The relative expression levels of TNF-α and IL-17RA genes were tested, and the results are as follows: Figure 1 As shown.

[0044] According to the test results, the relative expression levels of IL-17 RA and TNF-α genes in the model control groups at different concentrations were significantly downregulated compared with the blank control group, indicating that the stimulation conditions in this test were effective.

[0045] Compared with the blank control group, the relative expression level of IL-17 RA gene in the model control group was significantly downregulated at concentrations of 0.0125%, 0.025%, and 0.05%, with downregulation rates of 26%, 30%, and 38%, respectively; the relative expression level of TNF-α gene was downregulated by 21%, 30%, and 35% compared with the blank control group.

[0046] Compared with the blank control group, the relative expression level of IL-17 RA gene in the composition of Example 3 was significantly downregulated at concentrations of 0.0125%, 0.025%, and 0.05%, with downregulation rates of 30%, 33%, and 45%, respectively; the relative expression level of TNF-α gene was downregulated by 36%, 40%, and 45% compared with the blank control group.

[0047] The results above indicate that both the formulation of Example 3 and camellia extract alone have soothing effects; however, at the same concentration, the formulation combination of Example 3 has a better soothing effect than camellia extract alone.

[0048] Example 2 – HaCaT Cell Migration Rate Test The camellia composition of Example 2 was applied to keratinocytes, and cell migration rate was tested using the cell scratch assay.

[0049] 1. The testing method includes the following steps: 1) Vaccination: at 5.5 × 10 5 HaCaT cells were seeded into 6-well plates at a seeding density of cells / well and incubated overnight in an incubator (37°C, 5% CO2).

[0050] 2) Solution preparation: Prepare the sample working solution according to the grouping scheme shown in Table 4 below: Table 4 Grouping Scheme

[0051] 3) Drug administration: When the cell deposition rate in the 6-well plate reaches approximately 90%, administer the drug according to the grouping scheme in Table 4, with 2 mL of drug per well and 3 replicates per group. Continue culturing in an incubator (37℃, 5% CO2) for 24 h.

[0052] 4) Scratching: After the sample incubation is complete, scratch the plate. Use a 5mL pipette tip to make two vertical scratches in the six-well plate, using the vertical scratches as the baseline. After making the vertical scratches, make horizontal scratches near the center axis of the six-well plate, perpendicular to the baseline.

[0053] 5) Washing: After the scratching is completed, wash the cells 3 times with PBS, add normal cell culture medium, and incubate in an incubator (37℃, 5% CO2) for 24 hours.

[0054] 6) Photographs: Take a picture under a 4x microscope 0 hours after the scratch. After 24 hours, wash with PBS once and take a picture under a 4x microscope.

[0055] 2. Statistical Analysis of Results GraphPadPrism was used for plotting, and the results are represented as Mean+SD. t-tests were used for comparisons between groups. All statistical analyses were two-tailed. P < 0.05 was considered statistically significant, and P < 0.01 was considered highly statistically significant.

[0056] The results are shown in Table 5 below. Figure 2 As shown: Table 5 Summary of Cell Migration Rate Data Results

[0057] In Table 5, This means 0.01 ≤ P < 0.05; This means 0.001 ≤ P < 0.01; Figure 1 and Figure 2 middle, This means 0.01 ≤ P < 0.05; This means 0.001 ≤ P < 0.01; This indicates that P < 0.001.

[0058] The smaller the p-value, the better the experimental results.

[0059] From Table 5 and Figure 2 The results show that the relative cell migration rate in the PC group was significantly higher than that in the BC group, indicating that the positive control in this test was effective.

[0060] Compared with group BC, the relative cell migration rate of the camellia composition in Example 2 increased significantly, with an improvement rate of 15.3%. Therefore, the camellia composition of the present invention can significantly improve the cell migration rate of HaCaT cells, which is beneficial for inhibiting wound infection and promoting wound healing; the eight targets work together, complement each other, and synergistically enhance the soothing effect, effectively improving symptoms such as skin redness, itching, tightness, peeling, stinging, burning, childhood eczema, and skin allergies.

[0061] Example 3 – Skin Irritation Safety Test Experimental method: The human skin patch test was conducted in accordance with the "2015 Cosmetic Safety Technical Specifications".

[0062] The method for closed patch testing is as follows: 30 individuals aged 18-60 years are selected, and patches with an area not exceeding 50 mm are used. 2 A qualified spot test apparatus with a depth of approximately 1 mm was used. 0.020 mL of the compositions prepared in the above examples and comparative examples was placed inside the spot test apparatus chamber. The control well was a blank control (without any substance). The spot test apparatus containing the composition was applied to the flexor side of the subject's forearm using hypoallergenic adhesive tape, and the palm was gently pressed to ensure even application to the skin for 24 hours. Skin reactions were observed according to the standards in Table 5 at 30 minutes (after the indentation disappeared), 24 hours, and 48 hours after removing the spot test apparatus containing the composition, and the results were recorded.

[0063] The skin reaction grading criteria are shown in Table 6 below: Table 6. Grading Criteria for Skin Reactions in Closed Patch Tests

[0064] The test results are shown in Table 7 below: Table 7 Results of Skin Occlusive Patch Test

[0065] Experimental results show that the compositions of the above embodiments and comparative examples can all pass the human skin patch safety test.

[0066] Application Example 1 This application example provides the use and preparation method of camellia flower composition in the preparation of essential oils. The specific formulation is shown in Table 8 below: Table 8 Essential Oil Formula Table

[0067] The camellia extract in phase A above includes 21.384% camellia seed oil, 1.2% camellia flower extract, and 1% camellia leaf extract.

[0068] Preparation process: 1. Preparation of Phase A: Weigh out the solvent (caprylic / capric triglyceride), camellia extract, squalane, C15-19, dioctyl ether, 4-tert-butylcyclohexanol, stearyl glycyrrhetinic acid ester, and tocopherol (vitamin E) by mass percentage, heat to 80-90℃, mix and stir until completely clear and transparent to obtain the Phase A mixture. 2. Preparation of Phase B: Weigh bisabolol, Artemisia annua leaf extract, Chrysanthemum morifolium oil and fragrance according to the mass percentage, and stir until completely clear and transparent to obtain the Phase B mixture; 3. Mixing phases A and B: While stirring, slowly add phase B mixture to phase A mixture and stir until a transparent mixture is obtained, resulting in an essential oil containing camellia extract and a multi-soothing and repairing combination.

[0069] Application Example 2 This application example demonstrates the use and preparation method of camellia flower compositions in skincare cream formulations. The specific formulation is as follows: Phase A Water was replenished to a total of 100% for phases A, B, C, and D. Glycerin 5.0%; Butanediol 4.0%; Xanthan gum 0.1%; p-Hydroxyacetophenone 0.5%; 1,2-Hexanediol 0.5%; Ammonium acryloyldimethyltaurate / VP copolymer 0.3%; Sodium stearoyl glutamate 0.1%; Phase B Caprylic / capric triglyceride 5%; Isonononyl isononanoate 4%; MONTANOV 68 MB 0.8%; Emulium® Mellifera MB 0.8%; Cetearyl alcohol 0.5%; C phase SIMULGEL NS 0.8%; D phase Camellia flower composition (Example 3) 5.0%; Fragrance 0.1%.

[0070] Its preparation method is as follows: 1. At room temperature, add item A to the water pot in sequence, stir thoroughly to disperse evenly, then heat to 90±2℃, stir evenly, and then transfer to the emulsification pot, homogenize for 5 minutes, and stir evenly. 2. At room temperature, add item B to the oil pan in sequence, heat to 85±2℃, and after it is completely dissolved, transfer it to the emulsification pan. 3. Homogenize for 10 minutes, add item C, keep warm for 15 minutes, and stir well; 4. At 50±2℃, add item D and stir well.

[0071] The specific embodiments of the present invention have been described above. It should be understood that the present invention is not limited to the specific embodiments described above, and those skilled in the art can make various modifications or variations within the scope of the claims, which do not affect the essence of the present invention.

Claims

1. A camellia composition with soothing and repairing effects, characterized in that, The components include the following mass percentages: Camellia extract 5-99.0%, 4-tert-butylcyclohexanol 0.01~5.0%, Bisabolol 0.01~2.0%, Stearyl glycyrrhetinic acid ester 0.001~5.0%, Artemisia annua extract 0.001~2.0%, Chamomile essential oil 0.001~2.0%, Replenish the solvent to 100%.

2. The camellia composition according to claim 1, characterized in that, The camellia extract includes camellia seed oil, camellia flower extract, and camellia leaf extract, with a mass ratio of 70-99.8:0.1-15:0.1-15.

3. The camellia composition according to claim 1, characterized in that, The purity of the 4-tert-butylcyclohexanol is ≥99%; And / or, the bisabolol is of natural origin, wherein the purity of levo-α-bisabolol is ≥95%; And / or, the purity of the stearyl glycyrrhetinic acid ester is ≥98%.

4. The camellia composition according to claim 1, characterized in that, The artemisia extract includes one or more of Artemisia annua extract and Artemisia annua leaf extract.

5. The camellia composition according to claim 1, characterized in that, The chamomile essential oil includes one or more of Roman chamomile essential oil and German chamomile essential oil.

6. The camellia composition according to claim 1, characterized in that, The solvent includes natural oils or synthetic oils, and the solvent is selected from caprylic / capric triglycerides or squalane.

7. A method for preparing a camellia composition as described in any one of claims 1-6, characterized in that, Includes the following steps: S1, A phase preparation: Camellia extract, 4-tert-butylcyclohexanol and stearyl glycyrrhetinic acid ester were weighed into solvent according to mass percentage, mixed, heated and stirred until completely clear and transparent to obtain phase A mixture; S2, B phase preparation: Weigh bisabolol, artemisia annua extract and chamomile essential oil according to the mass percentage, mix and stir evenly until completely clear and transparent to obtain the B phase mixture; S3, A, B phase mixture: While stirring, slowly add the B phase mixture to the A phase mixture, and stir until it is uniform and transparent.

8. The preparation method according to claim 7, characterized in that, In step S1, the heating and stirring temperature is 80-90 ℃.

9. The use of a camellia composition as described in any one of claims 1-6 in the preparation of a skin care product having soothing and repairing effects.

10. The application according to claim 9, characterized in that, The skincare products include facial oils, creams, lotions, or masks.

Images